P159: Implementation of ultra rapid long read genome sequencing inclusion criteria improves diagnostic yield, impacts management, saves costs, and changes policies

Rapid exome (rES) and genome sequencing (rGS) have been shown to be valuable genetic testing tools in Neonatal ICU and Pediatric ICU to improve diagnostic yield and help save cost. However, lack of consistent multidisciplinary inclusion and exclusion criteria and workflow amongst major US healthcare systems hindered access, turn-around time (TAT), proper utilization, laboratory reimbursements, and polices. Moreover, the recent development in long read genome sequencing (LR-GS) and the availability of ultra-rapid turn-around time (TAT) represented unique opportunities for critically-ill pediatric patients to improve diagnostic yield and impact management.